REVIEW ON EVALUATING THE ROLE OF NSAIDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Recently, several studies have been reported that nonsteroidal anti-inflammatory drugs can fight against neurodegenerative disorders by various mechanisms. Currently, available therapies of neurodegenerative disorders (NDs) provide only symptomatic relief. This is the point at which we need an alternative that acts on the root cause of disease. Parkinson’s disease and Alzheimer’s disease are the two NDs concentrated here. Since the drug profile is already known, drug repurposing is a promising technique in research, thereby reducing the cost and period effectively. Epidemiological studies on various nonsteroidal anti-inflammatory drugs (NSAIDs) showed good results, but when it came to clinical studies the results are found to be poor. Hence, it can be concluded that NSAIDs provide its neuroprotective activity on its long-term use only, as the brain accessibility of this kind of drug is poor due to its lower lipophilicity.
2. Gaugler J, James B, Johnson T, Marin A, Weuve J. Alzheimer’s disease facts and figures. Alzheimers Dement 2020;16:391–460.
3. Sheikh S, Safia, Haque E, Mir SS. Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions. J Neurodegener Dis 2013;1–8. https://doi.org/ 10.1155/2013/563481.
4. Ali MM, Ghouri RG, Ans AH, Akbar A, Toheed A. Recommendations for anti-inflammatory treatments in alzheimer’s disease: a comprehensive review of the literature. Cureus 2019;11:e4620.
5. McGeer PL, McGeer EG. NSAIDs and alzheimer's disease: epidemiological, animal model, and clinical studies. Neurobiol Aging 2007;28:639–47.
6. Nade VS, Mardhekar VY, Bhoye UR, Kawale LA. Investigation of the neuroprotective effect of linagliptin and celiprolol in reserpine-induced orofacial dyskinesia and rotenone-induced neurodegeneration in rats. Int J Curr Pharm Res 2020;12:63–71.
7. Karran E, Palmer AM. Neurodegenerative disorders and their treatment. Drug News Perspect 2007;20:407–12.
8. Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Cofield M, et al. Clinical trial of indomethacin in alzheimer's disease. Neurology 1993;43:1990-3.
9. Arya MA, Maneesha K, Sabitha M, Krishnakumar NM, Sreeja CN. Nanotechnology approaches for enhanced CNS delivery in treating alzheimer's disease. J Drug Delivery Sci Technol 2019;51:297-309.
10. Bhor RJ. A review on “new treatment strategies for alzheimer’s disease as neurodegenerative disease and its risk factor cause, symptoms, and treatment at worldwide.” Asian J Pharm Clin Res 2016;9:16–22.
11. Giroud M, Sirisaengtaksin N, Bean AJ. Molecular mechanisms of neurological disease [Internet]. Third Edit. From Molecules to Networks: An Introduction to Cellular and Molecular Neuroscience: Third Edition. Elsevier Inc.; 2014. p. 639–61.
12. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drug Aging 2009;26:769-79.
13. Khanna K, Gambhir S, Gambhir M. Current challenges in detection of parkinson’ s disease. J Crit Rev 2020;7:1461–7.
14. DeMaagd G, Philip A. Parkinson’s disease and its management. Pharm Ther 2015;40:504-10.
15. Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44(Suppl 1):S89-S98.
16. Coupe C, Gordon PH. Amyotrophic lateral sclerosis-clinical features, pathophysiology, and management. Eur Neurol Rev 2013;8:38–44.
17. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009;4:1–22.
18. Geschwind MD. Prion diseases. Continuum (Minneap Minn) 2015;21:1612–38.
19. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis 2010;5:40.
20. Terzi M, Altun G, Sen S, Kocaman A, Kaplan AA, Yurt KK, et al. The use of non-steroidal anti-inflammatory drugs in neurological diseases. J Chem Neuroanat 2018;87:12–24.
21. Veld BA, Ruitenberg A, Hofman A, Launer LJ, Duijn CMV, Stijnen T, et al. Nonsteroidal anti-inflammatory drugs and the risk of intracerebral hemorrhage. N Engl J Med 2001;345:1515–21.
22. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurosci 2010;6:405–10.
23. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem 2012;11:52-64.
24. Benny A, Thomas J. Essential oils as treatment strategy for alzheimer’s disease current and future prespectives. Planta Med 2019;85:239-48.
25. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003;27:325–55.
26. Calabrese V, Bates TE, Giuffrida Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 2000;25:1315–41.
27. Khansari PS, Coyne L. NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacol 2012;20:159–67.
28. Benito Leon J, Contador I, Vega S, Villarejo Galende A, Bermejo Pareja F. Non-steroidal anti-inflammatory drugs use in older adults decreases risk of alzheimer’s disease mortality. PLoS One 2019;14:1–13.
29. Martyn C. Anti-inflammatory drugs and alzheimer’s disease. Br Med J 2003;327:354–5.
30. De Jong D, Jansen R, Hoefnagels W, Jellesma Eggenkamp M, Verbeek M, Borm G, et al. No effect of one-year treatment with indomethacin on alzheimer's disease progression: a randomized controlled trial. PLoS One 2008;3:e1475.
31. Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002;58:1050-4.
32. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, Mclendon DC, et al. NSAIDs and enantiomers of flurbiprofen target. J Clin Investig 2003;112:440–9.
33. Joo Y, Kim HS, Woo RS, Cheol HP, Shin KY, Lee JP, et al. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in vitro and in vivo Alzheimer's disease models. Mol Pharmacol 2006;69:76–84.
34. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord 2006;23:8–21.
35. Safitri I, Hidayati HB, Turchan A, Suhartati, Khaerunnisa S. Solanum betaceum improves cognitive function by decreasing n-methyl-d-aspartate on alzheimer rats model. Int J Appl Pharm 2019;11:167-70.
36. Small GW, Siddarth P, Silverman DHS, Ercoli LM, Miller KJ, Lavretsky H, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am J Geriatr Psychiatry 2008;16:999–1009.
37. Zhang J, Sui J, Chi BC, Wei NC. Protein profile in neuroblastoma cells incubated with S-and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: Possible action of induced proteins on Alzheimer’s disease. Proteomics 2008;8:1595–607.
38. Pasqualetti P, Bonomini C, Forno GD, Paulon L, Sinforiani E, Marra C, et al. A randomized controlled study on effects of ibuprofen on the cognitive progression of Alzheimer's disease. Aging Clin Exp Res 2009;21:102–10.
39. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces A?, hyperphosphorylated tau, and memory deficits in Alzheimer mice. Brain Res 2008;1207:225–36.
40. Szekely CA, Breitner JCS, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the cardiovascular health study: role of APOE and NSAID type. Neurology 2008;70:17–24.
41. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomized phase II trial. Lancet Neurol 2008;7:483–93.
42. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer's disease. Neurology 2008;70:1672–7.
43. Stuve O, Weideman RA, McMahan DM, Jacob DA, Little BB. Diclofenac reduces the risk of Alzheimer’s disease: a pilot analysis of NSAIDs in two US veteran populations. Ther Adv Neurol Disord 2020;13. DOI:10.1177/1756286420935676.
This work is licensed under a Creative Commons Attribution 4.0 International License.